Covid nasal spray company seeks major lender to develop its treatment
An Israeli doctor working on an experimental treatment for Covid wants to partner with the world’s largest pharmaceutical companies, such as AstraZeneca, to develop the treatment.
Nadir Arber has been working on a drug called EXO-CD24 that could turn severe cases of Covid-19 into manageable medical events.
The drug, now in a phase three study, aims to stop the ‘cytokine storm’ that affects the lungs of some patients.
The drug aims to stop the ‘cytokine storm’ that affects the lungs of some patients
This is a response where the immune system starts attacking healthy cells with extra cytokine proteins after infection by the virus. The drug can be administered through a nasal spray or inhaler.
dr. Arber, who works at the Tel Aviv Sourasky Medical Center, told The Mail on Sunday: “We’d like to partner with other companies.
“We are already in talks with a number of American companies, but it would also be nice to explore the possibility of working with AstraZeneca.”
dr. Arber said his firm was working with investment banking advisors to secure funding from strategic partners as his team sought more than $20 million (£15 million) for the drug’s development, with the goal of FDA approval. , the US medical regulator.
AstraZeneca declined to comment.